HPV vaccination impact on a cervical cancer screening program

Methods of the FASTER-tlalpan study in Mexico

Jorge Salmerón, Leticia Torres-Ibarra, F. Xavier Bosch, Jack Cuzick, Attila Lörincz, Cosette M. Wheeler, Philip E. Castle, Claudia Robles, Eduardo Lazcano-Ponce

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalSalud Publica de Mexico
Volume58
Issue number2
StatePublished - 2016

Fingerprint

Mexico
Early Detection of Cancer
Uterine Cervical Neoplasms
Vaccination
Vaccines
Safety
Health Services
Primary Health Care
Clinical Trials
Control Groups
Infection
Therapeutics

Keywords

  • Cervical intraepithelial neoplasia
  • Hpv
  • Mass screening
  • Mexico
  • Vaccination

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Salmerón, J., Torres-Ibarra, L., Xavier Bosch, F., Cuzick, J., Lörincz, A., Wheeler, C. M., ... Lazcano-Ponce, E. (2016). HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-tlalpan study in Mexico. Salud Publica de Mexico, 58(2), 211-219.

HPV vaccination impact on a cervical cancer screening program : Methods of the FASTER-tlalpan study in Mexico. / Salmerón, Jorge; Torres-Ibarra, Leticia; Xavier Bosch, F.; Cuzick, Jack; Lörincz, Attila; Wheeler, Cosette M.; Castle, Philip E.; Robles, Claudia; Lazcano-Ponce, Eduardo.

In: Salud Publica de Mexico, Vol. 58, No. 2, 2016, p. 211-219.

Research output: Contribution to journalArticle

Salmerón, J, Torres-Ibarra, L, Xavier Bosch, F, Cuzick, J, Lörincz, A, Wheeler, CM, Castle, PE, Robles, C & Lazcano-Ponce, E 2016, 'HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-tlalpan study in Mexico', Salud Publica de Mexico, vol. 58, no. 2, pp. 211-219.
Salmerón J, Torres-Ibarra L, Xavier Bosch F, Cuzick J, Lörincz A, Wheeler CM et al. HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-tlalpan study in Mexico. Salud Publica de Mexico. 2016;58(2):211-219.
Salmerón, Jorge ; Torres-Ibarra, Leticia ; Xavier Bosch, F. ; Cuzick, Jack ; Lörincz, Attila ; Wheeler, Cosette M. ; Castle, Philip E. ; Robles, Claudia ; Lazcano-Ponce, Eduardo. / HPV vaccination impact on a cervical cancer screening program : Methods of the FASTER-tlalpan study in Mexico. In: Salud Publica de Mexico. 2016 ; Vol. 58, No. 2. pp. 211-219.
@article{03cf13c0eb204f02a3dc0d04b2396e3d,
title = "HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-tlalpan study in Mexico",
abstract = "Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.",
keywords = "Cervical intraepithelial neoplasia, Hpv, Mass screening, Mexico, Vaccination",
author = "Jorge Salmer{\'o}n and Leticia Torres-Ibarra and {Xavier Bosch}, F. and Jack Cuzick and Attila L{\"o}rincz and Wheeler, {Cosette M.} and Castle, {Philip E.} and Claudia Robles and Eduardo Lazcano-Ponce",
year = "2016",
language = "English (US)",
volume = "58",
pages = "211--219",
journal = "Salud Publica de Mexico",
issn = "0036-3634",
publisher = "Instituto Nacional de Salud Publica",
number = "2",

}

TY - JOUR

T1 - HPV vaccination impact on a cervical cancer screening program

T2 - Methods of the FASTER-tlalpan study in Mexico

AU - Salmerón, Jorge

AU - Torres-Ibarra, Leticia

AU - Xavier Bosch, F.

AU - Cuzick, Jack

AU - Lörincz, Attila

AU - Wheeler, Cosette M.

AU - Castle, Philip E.

AU - Robles, Claudia

AU - Lazcano-Ponce, Eduardo

PY - 2016

Y1 - 2016

N2 - Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.

AB - Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.

KW - Cervical intraepithelial neoplasia

KW - Hpv

KW - Mass screening

KW - Mexico

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84970006747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970006747&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 211

EP - 219

JO - Salud Publica de Mexico

JF - Salud Publica de Mexico

SN - 0036-3634

IS - 2

ER -